Cancers

Article	Citations
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence	783
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review	424
A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis	288
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy	265
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer	235
The Landscape of Targeted Therapies in TNBC	219
The Application of Deep Learning in Cancer Prognosis Prediction	212
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy	205
The CCL5/CCR5 Axis in Cancer Progression	199
Molecular Biology of Osteosarcoma	189
The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response	178
Organoid and Spheroid Tumor Models: Techniques and Applications	177
STING Agonists as Cancer Therapeutics	177
Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies	174
Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy	168
CA125 and Ovarian Cancer: A Comprehensive Review	166
DNA Damage/Repair Management in Cancers	163
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies	161
Green Chemistry Synthesis of Silver Nanoparticles and Their Potential Anticancer Effects	160
Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment	159
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer	153
The Warburg Effect 97 Years after Its Discovery	148
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer	147
A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies	143
The Role of Macrophages in Cancer Development and Therapy	141

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance	141
Interleukin-1β and Cancer	140
Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer	139
Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis	138
The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities	136
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors	134
Epidemiology of Glioblastoma Multiforme–Literature Review	132
Photodynamic Therapy: A Compendium of Latest Reviews	132
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies	129
Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations	128
Novel Transfer Learning Approach for Medical Imaging with Limited Labeled Data	125
IL-12 Family Cytokines in Cancer and Immunotherapy	122
Cannabidiol (CBD) as a Promising Anti-Cancer Drug	121
DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy	120
Personalized Medicine: Recent Progress in Cancer Therapy	118
Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities	117
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance	117
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma	115
The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review	114
The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy	113
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis	111
Three-Dimensional Culture System of Cancer Cells Combined with Biomaterials for Drug Screening	110
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma	110
Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries	109
Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment	107
Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer	106
Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis	106
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer	106
Molecular Bases of Drug Resistance in Hepatocellular Carcinoma	105
The Role of p53 Signaling in Colorectal Cancer	104
FLASH Proton Pencil Beam Scanning Irradiation Minimizes Radiation-Induced Leg Contracture and Skin Toxicity in Mice	104
Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine	104
Flavonoids in Cancer Metastasis	103
Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach	102
Non-Invasive Biomarkers for Early Detection of Breast Cancer	102
Inflammatory Mechanisms of HCC Development	101
Extracellular Glutathione Peroxidase GPx3 and Its Role in Cancer	100
Tumor-Associated Macrophage Status in Cancer Treatment	100
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma	100
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives	100
Epigenetic Associations between lncRNA/circRNA and miRNA in Hepatocellular Carcinoma	100
Carbon Ion Radiobiology	99
A Review of Circulating Tumour Cell Enrichment Technologies	99
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression	98
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer	98
The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment	97
Gold Nanoparticles as a Potent Radiosensitizer: A Transdisciplinary Approach from Physics to Patient	97
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II	95
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives	93
The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC)	93

The Role of Probiotics in Cancer Prevention	92
Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK	91
RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field	91
Characterization of Human NK Cell-Derived Exosomes: Role of DNAM1 Receptor in Exosome-Mediated Cytotoxicity against Tumor	91
The Role of Cancer-Associated Fibroblasts in Tumor Progression	91
The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis	91
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death	90
Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany	90
Mechanisms of Taxane Resistance	89
Arginine Signaling and Cancer Metabolism	88
Chemotherapy Side-Effects: Not All DNA Damage Is Equal	88
Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations	88
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)	87
Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma	87
Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy	87
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update	87
Immune Escape Mechanisms in Non Small Cell Lung Cancer	87
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives	86
Emerging Therapies for Hepatocellular Carcinoma (HCC)	85
Oral–Gut Microbiome Axis in Gastrointestinal Disease and Cancer	85
Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment	85
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity	84
Stimuli-Responsive Hydrogels for Cancer Treatment: The Role of pH, Light, Ionic Strength and Magnetic Field	84
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy	83
New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines	83
Neutrophil Extracellular Traps (NETs) in Cancer Invasion, Evasion and Metastasis	83
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment	83
Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine	83
Diffusion-Weighted Imaging in Oncology: An Update	82
MicroRNA Therapeutics in Cancer: Current Advances and Challenges	82
Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets	82
Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments	81
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy	81
Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Ration	80
Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study	80
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy	80
Cancer and Aging: Two Tightly Interconnected Biological Processes	80
Light Technology for Efficient and Effective Photodynamic Therapy: A Critical Review	80
Immune Resistance in Lung Adenocarcinoma	80
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy	80
Mechanisms of Resistance to KRASG12C Inhibitors	80
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions	79
Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease	79
Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications	79
Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion	78
Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions	78
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer	78
Cyclic Hypoxia: An Update on Its Characteristics, Methods to Measure It and Biological Implications in Cancer	78
The Emerging Roles of RNA Modifications in Glioblastoma	78
Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation	78
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter	77
Glucose Transporters as a Target for Anticancer Therapy	77
Transfer Learning in Breast Cancer Diagnoses via Ultrasound Imaging	77
Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting	76
The Exciting New Field of HER2-Low Breast Cancer Treatment	76
The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis	76
Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial–Mesenchymal Transition	76
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far	76
Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis	75
Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness	75
Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment	75
A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy	75
Tunneling Nanotubes and Tumor Microtubes in Cancer	75
Evolution of the Experimental Models of Cholangiocarcinoma	74
3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs	74
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review	73
Neuroprotection of Radiosensitive Juvenile Mice by Ultra-High Dose Rate FLASH Irradiation	73
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)	73
EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis	73
Carbon Dots as Promising Tools for Cancer Diagnosis and Therapy	73
Role of MSC in the Tumor Microenvironment	73
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy	73
Cancer Stem Cells—Key Players in Tumor Relapse	73
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene	72
Radioresistance in Glioblastoma and the Development of Radiosensitizers	72
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review	72
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology	72
Friend or Foe: S100 Proteins in Cancer	71
Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches	71
The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy	71

Plasma-Treated Solutions (PTS) in Cancer Therapy	70
Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine	70
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity	70
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy	70
Indolepropionic Acid, a Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing Oxidative Stress	70
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy	70
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy	70
Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential	70
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling	69
Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials	69
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview	69
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer	69
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations	69
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment	69
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival	69
Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics	69
Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality	69
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer	69
Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment	68
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges	68
Merkel Cell Polyomavirus and Merkel Cell Carcinoma	68
Radiomics of Liver Metastases: A Systematic Review	68
Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis	68
JAK-STAT Signalling Pathway in Cancer	68
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment	68
Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies	68
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives	68
Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters	67
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials	67
Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome	67
The Role of Artificial Intelligence in Early Cancer Diagnosis	67
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management	67
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer	67
Transcription Factors in Cancer Development and Therapy	67
Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma	67
Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance	66
The Dynamic Relationship of Breast Cancer Cells and Fibroblasts in Fibronectin Accumulation at Primary and Metastatic Tumor Sites	66
MMP9: A Tough Target for Targeted Therapy for Cancer	66
How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH	66
The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer	66
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?	66
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy	66
Trends in Research on Exosomes in Cancer Progression and Anticancer Therapy	66
Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights	66
RNA-Binding Proteins in Cancer: Functional and Therapeutic Perspectives	66
Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021	66
Mechanisms of Resistance to Conventional Therapies for Osteosarcoma	65
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology	65
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy	65
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer	65
ATF4-Dependent NRF2 Transcriptional Regulation Promotes Antioxidant Protection during Endoplasmic Reticulum Stress	65
Recent Advances in Immunotherapy for Hepatocellular Carcinoma	65
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions	65
Past, Present and Future of Oncolytic Reovirus	65
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma	65
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance	65
Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis	64
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy	64
Long Non-Coding RNA HOTAIR in Breast Cancer Therapy	64
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?	64
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives	64
Non-Coding RNAs as Mediators of Epigenetic Changes in Malignancies	64
Perspectives on the Role of Isoliquiritigenin in Cancer	64
Sex and Gender Disparities in Melanoma	64
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy	64
Carotenoids in Cancer Apoptosis—The Road from Bench to Bedside and Back	64
The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions	64
The Functional Role of Extracellular Matrix Proteins in Cancer	63
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence	63
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer	63
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?	63
Pathology and Classification of SCLC	63
Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?	63
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies	62
Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview	62
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice	62
Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update	62
Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations	62
Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies	62
Mechanosensitive Piezo Channels in Cancer: Focus on altered Calcium Signaling in Cancer Cells and in Tumor Progression	62
Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers	62
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets	62
Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin	62
The New Era of Immunotherapy in Gastric Cancer	61
Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study	61
The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis	61
MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review	61
Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis	61
O-GlcNAcylation and O-GlcNAc Cycling Regulate Gene Transcription: Emerging Roles in Cancer	60
Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers	60
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives	59
Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?	59
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas	59
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer	59
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer	59